Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Combination therapy for BPH is cost-effective, especially for men with larger prostates.

This study found that big chain pharmacies in Pennsylvania charged significantly higher prices for generic BPH medications compared to independent pharmacies, which had more regional price variation.

This study reported that various medications, including known agents like finasteride and testosterone as well as unexpected ones like certain psychotropics and statins, are linked to male infertility cases in the Vigibase database.

This review discusses the use of finasteride for treating androgenic alopecia in men and examines its potential impacts on health, such as anxiety, libido, and fertility, without presenting new clinical results.

This study found that finasteride was associated with increased erectile dysfunction in men with benign prostatic hyperplasia, but this association was not statistically significant in those with male androgenic alopecia.

This study concluded that two different finasteride tablet formulations are bioequivalent based on their pharmacokinetic profiles in a crossover trial with male subjects.

This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This study reported that invasomes, utilizing limonene as a component, enhanced the transdermal permeation of finasteride by over 21 times, indicating their potential as a novel drug delivery system.

This study developed a rapid and efficient in vitro method using high-performance liquid chromatography to screen for steroid 5 alpha-reductase inhibitors, determining inhibition constants for Finasteride and Epristeride.

This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

This study concluded that two formulations of finasteride were bioequivalent based on Cmax, AUC, and Tmax data from healthy volunteers.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This study found that the pharmacokinetic profile of finasteride capsules and tablets in healthy volunteers is bioequivalent.

This piece describes the EndoPump Male Enhancement supplement, which claims to enhance erections and libido, but notes that there is insufficient medical evidence supporting the efficacy of its ingredients for sexual health.

The two finasteride formulations are bioequivalent.

Finasteride for hair loss in young men increases the risk of sexual dysfunction.

This study found that the Mark Cuban Cost Plus Drug Company model offers substantial cost savings on men's health medications compared to Medicare and GoodRx, particularly for long-term treatments.

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

Dutasteride may become the top choice for treating hair loss.